Journal article

Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study.

Anat Stern, Carolyn D Alonso, Carolina Garcia-Vidal, Celia Cardozo, Monica Slavin, Michelle K Yong, Su Ann Ho, Seema Mehta Steinke, Robin K Avery, Philipp Koehler, Christof Scheid, Oliver A Cornely, Johan Maertens, Yasmine Abi Aad, David J Epstein, Genovefa A Papanicolaou, Dionysios Neofytos

J Antimicrob Chemother | Published : 2021

Abstract

OBJECTIVES: To evaluate the safety and efficacy of cidofovir for the treatment of double-stranded DNA (dsDNA) viral infections following allogeneic haematopoietic cell transplant (HCT). METHODS: This was a retrospective multicentre cohort study including adult HCT recipients who received ≥1 dose of IV-administered cidofovir for any dsDNA viral infection from 2006 to 2019. The objectives were to describe the rate of and risk factors for nephrotoxicity and virological response by the end of treatment (EOT). RESULTS: We included 165 patients from nine centres. Cidofovir was administered at 5 mg/kg/week (N = 115; 69.7%), 1 mg/kg/week (18; 10.9%), 3 mg/kg/week (12; 7.3%) or 1 mg/kg three times/we..

View full abstract